Nemluvio is now the first approved monoclonal antibody that specifically targets interleukin-31 receptor alpha ...

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo ...

Nemluvio, which was also approved for prurigo nodularis, becomes Galderma’s first approved biologic in its dermatology ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic ...

Swiss dermatology company Galderma has announced two European approvals for Nemluvio (nemolizumab) to treat both atopic ...

The medication, also approved in the United States, is the first approved monoclonal antibody that specifically blocks the ...

全球新药研发迎来突破性进展 Galderma首创单抗Nemluvio登陆欧洲市场 ...

在这个充满变革的时代，医药行业正以前所未有的速度向前迈进。2025年2月17日，医药板块以+0.66%的涨幅跑赢沪深300指数，这不仅仅是一个数字上的变化，更是整个行业蓬勃发展的缩影。在这一轮医药创新浪潮中，Galderma和恒瑞医药成为了焦点。

Galderma today announced that the United Kingdom (UK) Medicines and Healthcare products Regulatory Agency and Swissmedi ...

Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU). Nemluvio is ...

Galderma has won approval from the European Commission (EC) for subcutaneous injection Nemluvio (nemolizumab) for the treatment of atopic dermatitis (AD), becoming the latest pharmaceutical ...

(BUSINESS WIRE )--Galderma (SWX:GALD) today announced that the European Commission has approved Nemluvio for both moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union (EU).